Idexx Laboratories Inc /DE (IDXX) financials

Idexx Laboratories Inc /DE (IDXX) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Idexx Laboratories Inc /DE reported revenue of $4.30B, up 10.4% year over year, net income of $1.06B, diluted EPS of $13.08 and free cash flow of $1.04B.

Revenue (fiscal 2025)

$4.30B

Revenue growth (fiscal 2025)

10.4%

Net income (fiscal 2025)

$1.06B

Diluted EPS (fiscal 2025)

$13.08

Free cash flow (fiscal 2025)

$1.04B

Idexx Laboratories Inc /DE files with the U.S. Securities and Exchange Commission under CIK 0000874716, classified as In Vitro & In Vivo Diagnostic Substances.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.